Under the direction of CEO Benjamin Holmes, Nanochon, Inc. is set to revolutionize the treatment of cartilage loss and damage. The company’s Chondrograft™ implant, a 3D-printed synthetic high-performance material, is designed to replace lost or damaged cartilage while encouraging new growth. This novel technology could redefine the standard of care for patients who are not yet candidates for, or want to avoid, knee replacement but are in need of a durable, low-cost, off-the-shelf solution for cartilage restoration.
Now, Nanochon is reaching a critical milestone—the company’s first-in-human clinical trial is set to begin this month, marking a major step forward in its journey to bring minimally invasive, regenerative cartilage restoration to patients suffering from painful joint damage.